U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-QSB
(Mark One)[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended December 31, 2001.
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to
Commission File Number 0-14942
PRO-DEX, INC. (Exact name of small business issuer in its charter)
<u>Colorado</u> (State or other jurisdiction of incorporation or organization) 84-1261240 (IRS Employer Identification No.)
151 E. Columbine Avenue, Santa Ana, California 92707 (Address of principal executive offices)
Issuer's telephone number: (714) 241-4411
Check whether the issuer (1) has filed all reports required by Section 13 or 15(d) of the Exchange Act during the past 12 months (or such shorter period registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes [X] No []
The number of shares of the Registrant's no par value common stock outstanding as of January 31, 2002 was 8,787,300.
Transitional small business disclosure format:

Yes [] No [X]

Table of Contents

PART I	Financial Information	Page No.
Item 1.		
	Financial Statements Consolidated Balance Sheets	1-2
	Consolidated Statements of Operations	3-6
	Consolidated Statements of Cash Flow	7
	Notes to Consolidated Financial Statements	8-12
Item 2.		
	Management Discussion and Analysis	13-17
PART II	Other Information	
Item 1.	Legal Proceedings	17
Item 4.	Submission of Matter to a Vote of Security Holders	17
	<u>Signatures</u>	18

CONSOLIDATED BALANCE SHEETS

ASSETS

	December 31, 2001			June 30, 2001
		(unaudited)		
Current assets:	_		_	
Cash and cash equivalents	\$	92,000	\$	698,000
Funds held in escrow, net		1,930,000		2,164,000
Accounts receivable, net of allowance for doubtful				
accounts of \$43,000 and \$44,000		1,415,000		1,386,000
Inventories, net		3,212,000		3,007,000
Prepaid expenses		86,000		96,000
Total current assets	_	6,735,000	_	7,351,000
Property and equipment		3,722,000		3,625,000
Less accumulated depreciation		(2,554,000)		(2,361,000)
Net property and equipment	_	1,168,000	_	1,264,000
Other assets:				
Other		65,000		112,000
Real estate available for sale		471,000		471,000
Deferred taxes		1,097,000		761,000
Intangibles, net		1,541,000		1,785,000
Total other assets	_	3,174,000	_	3,129,000
Total assets	\$	11,077,000	\$	11,744,000

CONSOLIDATED BALANCE SHEETS - CONTINUED

LIABILITIES & SHAREHOLDERS' EQUITY

		December 31, 2001	_	June 30, 2001
Current liabilities:		(unaudited)		
Current portion of long-term debt to a shareholder	\$	79,000	Φ	79,000
Notes payable	Φ	197,000	Þ	204,000
Accounts payable		988,000		817,000
Accrued expenses		624,000		932,000
Deferred taxes		149,000		149,000
Income taxes payable		457,000		467,000
Total current liabilities			_	
Total current habilities		2,494,000	_	2,648,000
Long-term debt to a shareholder, net of current portion		242,000		250,000
Total liabilities		2,736,000	_	2,898,000
Shareholders' equity: Series A convertible preferred shares, no par value; liquidation preference of \$3.60 per share; 10,000,000 shares authorized; 78,129 shares issued and outstanding Common shares, no par value; 50,000,000 shares authorized; 8,787,300 shares issued and outstanding Accumulated deficit		283,000 15,020,000 (6,874,000) 8,429,000	_	283,000 15,020,000 (6,356,000) 8,947,000
Receivable for stock purchase Total shareholders' equity Total liabilities and shareholders' equity	\$	(88,000) 8,341,000 11,077,000	<u> </u>	(101,000) 8,846,000 11,744,000

CONSOLIDATED STATEMENTS OF INCOME

	Quarter ended December 3 2001 2000			
		(unaudited)		(unaudited)
Net sales	\$	2,162,000	\$	4,565,000
Cost of sales (Includes rent paid to a director of \$37,000 and \$89,000 for 2001 and 2000)		1,176,000		2,028,000
Gross profits		986,000		2,537,000
Operating expenses: Selling General and administrative		152,000 851,000		349,000 1,031,000
Research and development Amortization Unusual charges		328,000 122,000		433,000 124,000 424,000
Total operating expenses		1,453,000	_	2,361,000
Income (loss) from operations		(467,000)	_	176,000
Other income (expense): Other income (expense), net Interest (expense) Total	_	31,000 (20,000) 11,000	· <u> </u>	18,000 (198,000) (180,000)
Income (loss) from continuing operations before income taxes (credits)		(456,000)		(4,000)
Income taxes (credits)		(182,000)	_	(2,000)
Income (loss) from continuing operations		(274,000)		(2,000)
Income (loss) from discontinued operations (net of tax (credit)) of (\$156,000) and \$87,000)		(233,000)		38,000
Net income (loss)	\$	(507,000)	\$	36,000
Earnings per common and common equivalent share: Income (loss) from continuing operations Basic Diluted	\$	(0.03) (0.03)	\$	(0.00) (0.00)
Income (loss) from discontinued operations: Basic Diluted	\$	(0.03) (0.03)	\$	0.00 0.00

Net Income: Basic Diluted	\$ (0.06) (0.06)	\$ 0.00 0.00
Weighted average number of common and common equivalent shares outstanding:		
Basic	8,787,300	8,787,300
Diluted	8,787,300	9,022,150

CONSOLIDATED STATEMENTS OF INCOME

	Six months ended December 31, 2001 2000			
		(unaudited)	_	(unaudited)
Net sales	\$	5,332,000	\$	8,876,000
Cost of sales (Includes rent paid to a director of \$74,000 and \$177,000 for 2001 and 2000)		2,956,000	_	3,910,000
Gross profits		2,376,000	_	4,966,000
Operating expenses: Selling General and administrative Research and development Amortization Unusual charges	_	314,000 1,602,000 707,000 244,000	_	540,000 1,910,000 879,000 246,000 424,000
Total operating expenses		2,867,000	_	3,999,000
Income (loss) from operations		(491,000)	_	967,000
Other income (expense): Other income (expense), net Interest (expense) Total		54,000 (36,000) 18,000	_	36,000 (451,000) (415,000)
Income (loss) from continuing operations before income taxes (credits) Income taxes (credits)		(473,000) (188,000)	_	552,000 221,000
Income (loss) from continuing operations		(285,000)		331,000
Income (loss) from discontinued operations (net of tax (credit)) of (\$156,000) and \$87,000)		(233,000)	_	131,000
Net income	\$	(518,000)	\$_	462,000
Earnings per common and common equivalent share: Income (loss) from continuing operations Basic Diluted	\$	(0.03) (0.03)	\$	0.04 0.04
Income (loss) from discontinued operations: Basic Diluted	\$	(0.03) (0.03)	\$	0.01 0.01

Net Income:	¢.	(0.06)	¢.	0.05
Basic	\$	(0.06)	\$	0.05
Diluted		(0.06)		0.05
Weighted average number of common and common equivalent shares outstanding:				
Basic	;	8,787,300		8,787,300
Diluted	;	8,787,300		8,996,976

CONSOLIDATED STATEMENTS OF CASH FLOWS

CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss) \$ 462,000		Six months ended December 3 2001 2000			
Net income (loss) \$ (518,000) \$ 462,000 Adjustments to reconcile net income to net cash provided by operating activities: 37,000 601,000 Depreciation and amortization 437,000 601,000 Loss on Disposal of discontinued operations 234,000 Provision for doubtful accounts 1,000 90,000 Non-cash compensation 13,000 13,000 Deferred taxes (336,000) 266,000 Change in working capital components net of effects (30,000) 270,000 (Increase) decrease in accounts receivable (30,000) 270,000 (Increase) in inventories (205,000) (642,000) Decrease in other assets 47,000 185,000 (Decrease) in accounts payable 47,000 185,000 (Decrease) in income taxes payable (10,000) (47,000) Net cash provided by (used in) operating activities (494,000) 813,000 CASH FLOWS FROM INVESTING ACTIVITIES 1,000 8,000 Proceeds from sale of property and equipment (98,000) (120,000) Net cash flows (used in) investing activities		_	(unaudited)	_	(unaudited)
Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization Loss on Disposal of discontinued operations Provision for doubtful accounts Non-cash compensation Deferred taxes (336,000) Deferred taxes (336,000) Change in working capital components net of effects of purchases and divestitures: (Increase) decrease in accounts receivable (Increase) in inventories (Increase) in inventories (Increase) in prepaid expenses (Increase) in other assets (Decrease in accounts payable and accrued expenses (Increase) in income taxes payable (Decrease) in income taxes payable And accrued expenses (Increase) in income taxes payable And accrued expenses (Incre	CASH FLOWS FROM OPERATING ACTIVITIES				
cash provided by operating activities: 437,000 601,000 Depreciation and amortization 437,000		\$	(518,000)	\$	462,000
Depreciation and amortization					
Loss on Disposal of discontinued operations Provision for doubtful accounts 1,000 90,000 Non-cash compensation 13,000 13,000 Deferred taxes (336,000) 266,000 Change in working capital components net of effects of purchases and divestitures: (Increase) decrease in accounts receivable (30,000) (270,000 (Increase) decrease in accounts receivable (205,000) (642,000) Decrease (increase) in prepaid expenses 10,000 (217,000) Decrease in other assets 47,000 185,000 (Decrease) in accounts payable (137,000) (168,000) (Decrease) in income taxes payable (10,000) (47,000) (
Provision for doubtful accounts 1,000 90,000 Non-cash compensation 13,000 10,000					601,000
Non-cash compensation 13,000 266,000 2					
Deferred taxes					
Change in working capital components net of effects of purchases and divestitures:	*				
Of purchases and divestitures: (Increase) decrease in accounts receivable (30,000) (270,000 (10,000) (10,000) (10,000) (10,000) (2017,000) (642,000) (10,000) (217,000) (642,000) (10,000) (217,000) (10,000)			(336,000)		266,000
(Increase) decrease in accounts receivable (Increase) in inventories (30,000) (270,000) (642,000) Decrease (increase) in prepaid expenses 10,000 (217,000) Decrease in other assets 47,000 185,000 (Decrease) in accounts payable and accrued expenses (137,000) (168,000) (Decrease) in income taxes payable (10,000) (47,000) Net cash provided by (used in) operating activities (494,000) 813,000 CASH FLOWS FROM INVESTING ACTIVITIES The company of t					
Clacrease (increase) in prepaid expenses 10,000 (217,000) Decrease (increase) in prepaid expenses 10,000 (217,000) Decrease in other assets 47,000 185,000 (Decrease) in accounts payable (137,000) (168,000) (Decrease) in income taxes payable (10,000) (47,000) (Decrease) in income taxes payable (10,000) (47,000) Net cash provided by (used in) operating activities (494,000) 813,000 CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from sale of property and equipment 1,000 8,000 Purchase of property and equipment (98,000) (120,000) Net cash flows (used in) investing activities (97,000) (112,000) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds (payments) from short-term borrowing - 115,000 Principal proceeds (payments) on long-term borrowing (15,000) (1,111,000) Net cash flows (used in) financing activities (15,000) (996,000) Net cash flows (used in) financing activities (15,000) (295,000) Cash and cash equivalents, beginning of period (598,000) (473,000) Cash and cash equivalents, end of period (598,000) (398,000) SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest \$38,000 \$503,000					
Decrease (increase) in prepaid expenses					
Decrease in other assets					
(Decrease) in accounts payable and accrued expenses (137,000) (168,000) (Decrease) in income taxes payable (10,000) (47,000) Net cash provided by (used in) operating activities (494,000) 813,000 CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from sale of property and equipment 1,000 (98,000) (120,000) Net cash flows (used in) investing activities (97,000) (112,000) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds (payments) from short-term borrowing 1,500 (15,000) (1111,000) Principal proceeds (payments) on long-term borrowing (15,000) (1,111,000) Net cash flows (used in) financing activities (15,000) (996,000) NET DECREASE IN CASH AND CASH EQUIVALENTS (606,000) (295,000) Cash and cash equivalents, beginning of period 698,000 473,000 Cash and cash equivalents, end of period 92,000 \$178,000 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest \$38,000 \$503,000			,		
and accrued expenses (Decrease) in income taxes payable (137,000) (168,000) (47,000) Net cash provided by (used in) operating activities (494,000) 813,000 CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from sale of property and equipment Purchase of property and equipment 1,000 (98,000) (120,000) Net cash flows (used in) investing activities (97,000) (112,000) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds (payments) from short-term borrowing Principal proceeds (payments) on long-term borrowing - 115,000 (1,111,000) Net cash flows (used in) financing activities (15,000) (996,000) Net cash flows (used in) financing activities (606,000) (295,000) NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and cash equivalents, beginning of period (698,000) (473,000) (473,000) Cash and cash equivalents, end of period (292,000) (293,000) (293,000) (293,000) (293,000) SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (284, payments for interest) \$ 38,000 (380,000)			47,000		185,000
(Decrease) in income taxes payable (10,000) (47,000) Net cash provided by (used in) operating activities (494,000) 813,000 CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from sale of property and equipment Purchase of property and equipment (98,000) (120,000) Net cash flows (used in) investing activities (97,000) (112,000) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds (payments) from short-term borrowing Principal proceeds (payments) on long-term borrowing Net cash flows (used in) financing activities (15,000) (1,111,000) NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest (10,000) (499,000) (112,000)			(4.4.7.000)		(4.50.000)
Net cash provided by (used in) operating activities (494,000) 813,000 CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from sale of property and equipment (98,000) (120,000) Net cash flows (used in) investing activities (97,000) (112,000) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds (payments) from short-term borrowing Principal proceeds (payments) on long-term borrowing (15,000) (1,111,000) Net cash flows (used in) financing activities (15,000) (996,000) NET DECREASE IN CASH AND CASH EQUIVALENTS (606,000) (295,000) Cash and cash equivalents, beginning of period (698,000) (473,000) Cash and cash equivalents, end of period (990,000) (178,000) SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest (38,000) \$503,000					, ,
CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from sale of property and equipment Purchase of property and equipment Net cash flows (used in) investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds (payments) from short-term borrowing Principal proceeds (payments) on long-term borrowing Net cash flows (used in) financing activities Net cash flows (used in) financing activities NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest S 38,000 S 503,000	(Decrease) in income taxes payable	_	(10,000)	-	(47,000)
Proceeds from sale of property and equipment Purchase of property and equipment Net cash flows (used in) investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds (payments) from short-term borrowing Principal proceeds (payments) on long-term borrowing Net cash flows (used in) financing activities Net cash flows (used in) financing activities NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest 1,000 (97,000) (112,000) 115,000 (15,000) (15,000) (15,000) (295,000)	Net cash provided by (used in) operating activities	_	(494,000)	-	813,000
Purchase of property and equipment (98,000) (120,000) Net cash flows (used in) investing activities (97,000) (112,000) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds (payments) from short-term borrowing Principal proceeds (payments) on long-term borrowing (15,000) (1,111,000) Net cash flows (used in) financing activities (15,000) (996,000) NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and cash equivalents, beginning of period (698,000) (295,000) Cash and cash equivalents, end of period (990,000) (178,000) SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest (38,000) \$ 503,000	CASH FLOWS FROM INVESTING ACTIVITIES				
Purchase of property and equipment (98,000) (120,000) Net cash flows (used in) investing activities (97,000) (112,000) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds (payments) from short-term borrowing Principal proceeds (payments) on long-term borrowing (15,000) (1,111,000) Net cash flows (used in) financing activities (15,000) (996,000) NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and cash equivalents, beginning of period (698,000) (295,000) Cash and cash equivalents, end of period (990,000) (178,000) SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest (38,000) \$ 503,000	Proceeds from sale of property and equipment		1,000		8,000
Net cash flows (used in) investing activities (97,000) (112,000) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds (payments) from short-term borrowing Principal proceeds (payments) on long-term borrowing (15,000) (1,111,000) Net cash flows (used in) financing activities (15,000) (996,000) NET DECREASE IN CASH AND CASH EQUIVALENTS (606,000) (295,000) Cash and cash equivalents, beginning of period 698,000 473,000 Cash and cash equivalents, end of period 92,000 \$178,000 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest \$38,000 \$503,000			•		•
CASH FLOWS FROM FINANCING ACTIVITIES Proceeds (payments) from short-term borrowing Principal proceeds (payments) on long-term borrowing Net cash flows (used in) financing activities NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest CASH FLOW STROME		_		-	
Proceeds (payments) from short-term borrowing Principal proceeds (payments) on long-term borrowing Net cash flows (used in) financing activities (15,000) NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest 115,000 (996,000) (295,000) 473,000 \$ 92,000 \$ 178,000	Net cash flows (used in) investing activities	_	(97,000)	-	(112,000)
Principal proceeds (payments) on long-term borrowing (15,000) (1,111,000) Net cash flows (used in) financing activities (15,000) (996,000) NET DECREASE IN CASH AND CASH EQUIVALENTS (606,000) (295,000) Cash and cash equivalents, beginning of period 698,000 473,000 Cash and cash equivalents, end of period \$92,000 \$178,000 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION 38,000 \$503,000	CASH FLOWS FROM FINANCING ACTIVITIES				
Principal proceeds (payments) on long-term borrowing (15,000) (1,111,000) Net cash flows (used in) financing activities (15,000) (996,000) NET DECREASE IN CASH AND CASH EQUIVALENTS (606,000) (295,000) Cash and cash equivalents, beginning of period 698,000 473,000 Cash and cash equivalents, end of period \$92,000 \$178,000 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION 38,000 \$503,000	Proceeds (payments) from short-term borrowing				115,000
NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest (606,000) (295,000) 473,000 \$ 178,000 \$ 32,000 \$ 503,000	Principal proceeds (payments) on long-term borrowing	_	(15,000)	-	(1,111,000)
Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest \$ 38,000 \$ 503,000	Net cash flows (used in) financing activities	_	(15,000)		(996,000)
Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest \$ 38,000 \$ 503,000	NET DECREASE IN CASH AND CASH FOLITVALENTS		(606,000)		(295,000)
Cash and cash equivalents, end of period \$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\					, ,
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest \$ 38,000 \$ 503,000		\$		2	
INFORMATION Cash payments for interest \$ 38,000 \$ 503,000	Cash and cash equivalents, end of period	Ψ_	72,000	Ψ	170,000
	Cash payments for interest	\$	38,000	\$	503,000
					78,000

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For Quarter and Six months Ended December 31, 2001

BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB and Regulation S-B. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended December 31, 2001 are not necessarily indicative of the results that may be expected for the year ended June 30, 2002. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's annual report on Form 10-KSB for the year ended June 30, 2001.

INVENTORIES

Inventories are stated at the lower of cost (the first-in, first-out method) or market and consist of the following:

	<u>December 31, 2001</u>	<u>June 30, 2001</u>
Raw materials	\$ 718,000	\$ 826,000
Work in process	505,000	171,000
Finished goods	2,535,000	2,601,000
Total	3,758,000	3,598,000
Reserve for slow moving items	(546,000)	(591,000)
Total inventories, net	<u>\$ 3,212,000</u>	\$ 3,007,000

In determining reserves, management analyzes raw materials and finished goods for slow moving material. Inventory with more than 24 months of estimated usage on hand have been reserved at 20% of carrying value, more than 36 months have been reserved at 50%, more than 48 months have been reserved at 100%.

EARNINGS PER SHARE

The Financial Accounting Standards board has issued Statement No. 128, "Earnings per Share" which supercedes APB Opinion No. 15. Statement No. 128 requires the presentation of basic and diluted earnings per share amounts. Diluted per share amounts assume the conversion, exercise or issuance of all potential common stock instruments unless the effect is to reduce a loss or increase the income per common share from continuing operations. No adjustments to net income were made for purposes of computing basic or diluted earnings per share.

The weighted-average number of common shares and common share equivalents outstanding during the year used to compute basic and diluted earnings per common share is as follows:

	Quarter ended December 31, 2001	Six-months ended December 31, 2001	Quarter ended December 31, 2000	Six-months ended December 31, 2000
Weighted-average common shares used in computation of basic earnings per share	8,787,300	8,787,300	8,787,300	8,787,300
Effect of dilutive securities: Common stock options and warrants			156,721	131,547
Convertible preferred stock			78,129	78,129
Weighted-average common and common share equivalents used in the computation of diluted earnings per share	8,787,300	8,787,300	9, 022,150	8,996,976

Common shares issuable upon the exercise of employee stock options and common stock warrants are equivalent to 224 shares outstanding and the effect of 78,129 common shares that are issuable upon conversion of preferred stock have not been included in the 2001 computation because their inclusion would have been anti-dilutive.

LONG TERM DEBT

The total debt to a stockholder represents the net amount of an \$817,000 debt less a receivable from the same stockholder of \$496,000. Since the Company has a legal right to offset the note receivable against the note payable in the event of non-payment, the Company has presented the note payable net of the related note receivable. Both notes bear interest at 7%. The notes payable requires quarterly payments of \$50,000 through June 30, 2006. The note receivable requires quarterly payments of \$30,400 through June 30, 2006.

Following is a summary of long-term debt:

	<u>2002</u>	2001
Unsecured note to a stockholder, net of related receivable	\$ 321,000	\$ 329,000
Less current portion	 79,000	79,000
Total long-term debt	\$ 242,000	\$ 250,000

STOCK OPTIONS

During the quarter ended December 31, 2001, the Company granted 40,000 stock options to employees respectively at the average price of \$1.26 (average fair market value of \$0.70). The options vest over a period of four years, and expire in ten years.

WARRANTS

During six months ended December 31, 2001, the Company granted 24,000 warrants to a former employee for services rendered in connection with consulting services provided over the same six month period. The warrants were issued at an average price of \$0.975 (average fair market value of \$0.55) and vested upon issuance. The fair value of each warrant is estimated at the grant date using the Black-Scholes option pricing model with the following weighted average assumptions: no dividend rate for all years; price volatility of 58.2% to 68.3% in 2002; risk-free interest rates of approximately 4.5% to 4% in 2002; and, expected lives of five years.

BUSINESS DIVESTITURES AND DISCONTINUED OPERATIONS

On June 12, 2001, the Company sold substantially all of the assets of its two wholly owned subsidiaries, Biotrol International, Inc. and Challenge Products, Inc. to Young Colorado LLC, a newly formed subsidiary of Young Innovations, Inc., for a purchase price of \$9 million. The Company received \$6.6 million of the purchase price at the closing. The balance of the purchase price of \$2.4 million is escrowed to secure various warranties under the sale agreement. The Company has reserved \$500,000 for potential warranty obligations that may arise after the sale. The escrow agreement runs for fifteen months with various release dates during the period. The assets sold comprised the Company's line of infection control and preventive chemical products for the dental industry. The divestiture has been presented as discontinued operations and as such the consolidated statements of operations for the six months and quarter ended December 31, 2000 have been retroactively restated.

COMMITMENTS AND CONTINGENCIES

The Company has received indemnification notices by Young Colorado, LLC, the buyer of the operating assets of the Company's Biotrol and Challenge operations, to recover alleged losses and costs as they are incurred for certain alleged breaches of representations and warranties related to compliance issues with the Food, Drug, and Cosmetic Act (FDCA), Federal Insecticide, Fungicide and Rodentcide Act (FIFRA), Environmental and other related Laws contained in the Agreement for Purchase and Sale of Assets, dated as of June 12, 2001 between Pro-Dex, Inc. (Seller), and Young Colorado, LLC, (Buyer). In February 2002, the Company settled a complaint with the EPA related to the buyer's indemnification notice for alleged violations of FIFRA. As a result, the Company will pay \$150,000 to the EPA, payable over a 15 month period. In February, 2002, the Company received a notice from Young stating various amounts due under the Agreement. These indentified amounts totaled approximately \$200,000. In addition, the notices identified other matters but did not specify the amount of any claim, but asserts that their losses and compliance costs could exceed the entire escrow amount of \$2.4 million. Management reserved an additional \$150,000 for the unspecified claims. As a result of the settlement of the EPA matter and the notice received from Young, management increased the reserve for the escrow funds by \$260,000 during the second quarter of 2001 bringing the total reserve to \$500,000. Management recorded a charge, net of income tax effect, against discontinued operations for the increase in reserve plus additional items related to the sale. Management believes this reserve will be sufficient to provide for existing and future claims against the escrow account receivable, as it was determined through examining the legal costs to date, and projecting for the remaining issues.

SEGMENT INFORMATION

The Company's reportable segments are strategic business units that offer different products and services. They are managed separately because each business requires different technology and marketing strategies.

After the 2001 divestiture of the operations of Biotrol International, Inc., and Challenge Products, Inc., there are two reportable segments; (i) medical/dental equipment and, (ii) electronic motion controllers. The accounting policies applied to determine the segment information are the same as those described in the summary of significant accounting policies. Interest expense is allocated based upon the specific identification of debt incurred by the individual segment. Corporate overhead and the provision for income taxes are not allocated to the individual reported segments. Inter-segment sales and transfers are accounted for at amounts that management believes provides the transferring segment with fair compensation for the products transferred, considering their condition, market demand, and, where appropriate, a reasonable profit that recognized which segment will be responsible for marketing costs. Management evaluates the performance of each segment based on income (loss) before income taxes.

Revenue from discontinued operations totaled \$4,732,000 and \$2,744,000 respectively for the six months and quarter ended December 31, 2000. There was no allocation of corporate overhead to discontinued operations for the six months and quarter ended December 31, 2000.

Financial information with respect to the reportable segments follows (in thousands):

6 months ending December 31, 2001			Micro Motors	Oregon Micro Systems	Corp.	Total		
Sales from external	custome	rs	\$4,110	\$1,222		\$ 5,332		
Depreciation and an	mortizatio	on	169	230	38	437		
Interest expense			36			36		
Segment profit (los	s)		520	(273)	(720)	(473)		
Segment assets	,		5,643	1,563	3,871	11,077		
Expenditure for seg	gment ass	ets	75	23		98		
6 months ending December 31, 2000	Biotrol	Challenge	Micro Motors	Oregon Micro Systems	Corp.	Total	Reconciliation	Total
Sales from	\$4,247	\$ 485	\$3,688	\$5,051		\$ 13,471	(\$4,595)	\$8,876
external Customers	. ,		, ,	. ,		. ,	(, , ,	, ,
Intersegment sales		473	137			610	(610)	
Segment profit (loss)	566	(351)	(705)	2,616	(1,664)	462		462
Depreciation & Amortization	33	99	205	242	41	620	(132)	488
Interest Expense		56	429		18	503	(52)	451
Segment assets	2,440	1,198	6,484	3,428	2,136	15,686		15,686
Expenditure for segment assets	70	12	13	20	5	120		120

3 months ending December 31, 2001		Micro Motors	Oregon Micro Systems	Corp.	Total			
Sales from external co	ustomer	3	\$1,729	\$433		\$2,162		
Depreciation and amo	ortizatio	1	81	115	18	214		
Interest expense			19		1	20		
Segment profit (loss)			194	(211)	(490)	(507)		
Segment assets			5,643	1,563	3,871	11,077		
Expenditure for segm	ent asse	ts	20			20		
3 months ending December 31, 2000	e e		Micro Motors	Oregon Micro	Corp.	Total	Recon- ciliation	Total
				Systems				
Sales from external	\$2,523	\$ 221	\$1,936	\$2,570		\$7,250	(\$2,685)	\$4,565
Customers								
Intersegment sales		163	59			222	(222)	
Segment profit (loss)	382	(349)	(406)	1,307	(898)	36		36
Depreciation &	16	72	95	124	20	327	(88)	239
Amortization								
Interest Expense		26	207		(11)	222	(24)	198
Segment assets	2,440	1,198	6,484	3,428	2,136	15,686	` <u>-</u> -	15,686
Expenditure for segment	62		13	5		80		80
assets								

The segment amounts reported for 2000 have been reconciled to the consolidated financial statements as restated for the effect of discontinued operations.

Item 2. Management's Discussion and Analysis

Results of Operations

Forward Looking Statements. All forward looking statements in the following discussion of Management's Analysis of Results of Operation, Liquidity and Capital Resources, and the possible effect of inflation, as well as elsewhere in the Company's assumptions regarding factors such as (1) market acceptance of the products of each subsidiary, including brand and name recognition for quality and value in each of the Company's subsidiaries' markets. (2) existence, scope, defensibility and non-infringement of patents, trade-secrets and other trade rights, (3) each subsidiary's relative success in achieving and maintaining technical parity or superiority with competitors, (4) interest rates for domestic and Euro funds, (5) the relative success of each subsidiary in attracting and retaining technical and sales personnel with the requisite skills to develop, manufacture and market the Company's products, (6) the nonoccurrence of general economic downturns or downturns in any of the Company's market regions or industries (such as dental products and tools or computer chip manufacturers). (7) the relative competitiveness of products manufactured by the Company's facilities, including any contractors in the global economy, (8) the non-occurrence of natural and geopolitical disasters and events, (9) a stable regulatory environment in areas of significance to each of the Company's subsidiaries, (10) the Company's success in managing its regulatory relations and avoiding any adverse determinations, (11) the availability of talented senior executives for the Company and each of its subsidiaries, and (12) other factors affecting the sales and profitability of the Company and its subsidiaries in each of its respective markets. Should any of the foregoing assumptions or other assumptions not listed fail to be realized, the forward-looking statements herein may be inaccurate. In making forward looking statements in this and other Sections of the Company's report on this Form 10-QSB, the Company relies upon recently promulgated policies of the Securities and Exchange Commission and statutory provisions, including Section 21E of the Securities Exchange Act of 1934, which provide a safe-harbor for forward looking statements.

Results of Operations for the Quarter Ended December 31, 2001 Compared to the Quarter Ended December 31, 2000.

On June 12, 2001, the Company sold substantially all of the assets of its two wholly owned subsidiaries, Biotrol, International, Inc., and Challenge Products, Inc. to Young, LLC, a newly formed subsidiary of Young Innovations, Inc., for a purchase price of \$9 million. The Company received \$6.6 million of the purchase price at the closing. The balance of the purchase price of \$2.4 million is escrowed to secure various warranties under the sale agreement. The results of operations for the Biotrol and Challenge subsidiaries are reported as income from discontinued operations for the quarter ended December 31, 2001.

Net sales by subsidiary follows:

	2001	2000_	Increase/
			(Decrease)
Micro Motors	\$1,729,000	\$1,995,000	\$(266,000)
Oregon Micro Systems	433,000	2,570,000	(2,137,000)
	\$ 2,162,000 \$	4,565,000 \$	(2,403,000)

Consolidated sales decreased 53% for the quarter ended December 31, 2001, compared to the quarter ended December 31, 2000, primarily due to a decrease in sales orders, with the majority at the Company's wholly owned subsidiary Oregon Micro Systems, reflecting the continuing slowness in the semiconductor fabrication industry. At Micro Motors Inc., sales decreased 13% for the quarter ended December 31, 2001 compared to the quarter ended December 31, 2000. Sales of medical products fell 53% from \$411,000 in the quarter ended December 31, 2000 to \$191,000 in the quarter ended December 31, 2001 due to a customer directed delayed order delivery. Sales to dental customers fell 5% from \$1,282,000 to \$1,213,000 and sales to industrial customers rose 17% for the quarter from \$180,000 to \$211,000. Micro Motors sales are expected to improve in the next period as sales delayed from the second quarter should be realized in the third and fourth quarter of 2001. Revenue at Oregon Micro Systems decreased 83% for the quarter ended December 31, 2001 compared to the previous year's same quarter. The steep decline was caused by a severe reduction in orders from customers in the semiconductor fabrication equipment industry. There continues to be no sign of immediate recovery in the semiconductor industry. Management believes a strong sales effort at OMS continues to gain design wins that will provide opportunities for its products in the medical, semiconductor and distribution industries.

Gross profits by subsidiary follows:

		2001	2000	Increase/
				(Decrease)
Micro Motors		\$759,000	\$540,000	\$219,000
Oregon Micro Systems		227,000	1,997,000	(1,770,000)
	\$_	986,000	\$ 2,537,000	\$ (1,551,000)

The Company's consolidated gross profit for the quarter ended December 31, 2001 decreased 61% over the same quarter in the previous year due to reduced sales at OMS. Gross profit as a percentage of sales decreased to 46% for the quarter ended December 31, 2001 compared to 56% for the quarter ended December 31, 2000 caused by less absorption of manufacturing overhead due to lower sales. Gross profit dollars and percentage increased at Micro Motors due to sales of higher priced products.

Operating expenses decreased to \$1,453,000 for the quarter ended December 31, 2001 from \$1,937,000 (before unusual charges) for the quarter ended December 31, 2000, a decrease of 25%. The decrease is mainly due to the cost cutting at both OMS and Micro Motors and the consolidation of the Micro Motors offices in Santa Ana, California.

Net interest expense decreased \$178,000 in the second quarter of fiscal 2001 due to the payoff of the Company's entire bank debt on June 12, 2001, with the use of the proceeds from the sale of the Biotrol and Challenge operations.

The Company's effective tax rate on income (loss) from operations is 40% for the quarters ended December 31, 2001, and 2000. The Company's effective tax rate for income from discontinued operations is 40% for quarter ended December 31, 2000.

Net income from continuing operations decreased \$544,000 for the quarter ended December 31, 2001 compared to the quarter ended December 31, 2000. Lower sales and gross profits were the main reasons for the decrease. The Company incurred a net loss from discontinued operations of (\$233,000) net of taxes.

The Company sustained a net (loss) for the quarter ended December 31, 2001 of (\$508,000) compared to net income of \$36,000 for the quarter ended December 31, 2000.

Results of Operations for the Six Months Ended December 31, 2001 Compared to the Six Months Ended December 31, 2000.

Net sales by subsidiary follows:

	2001	2000	Increase/
			(Decrease)
Micro Motors	\$4,110,000	\$3,825,000	\$285,000
Oregon Micro Systems	1,222,000	5,051,000	(3,831,000)
-	\$ 5,332,000	\$ 8,876,000	\$ (3,544,000)

Consolidated sales decreased 40% for the six months ended December 31, 2001, compared to the six months ended December 31, 2000, primarily due to a decrease in sales at OMS, reflecting the continuing slowness in the semiconductor fabrication industry. At Micro Motors, sales increased 7% for the six months ended December 31, 2001 compared to the six months ended December 31, 2000. Sales to dental customers increased 17% from \$2,358,000 to \$2,745,000 as new product and development contract sales were realized. Sales to industrial customers fell 16% and sales of medical products were relatively flat, with a 1% decrease for the six months ended December 31, 2001 compared to the six months ended December 31, 2000 for a combined drop of \$97,000. Micro Motors sales are expected to improve in the next period as sales delayed from the second quarter should be realized in the third and fourth quarter of 2001. Revenue at OMS decreased 76% for the six months ended December 31, 2001 compared to the previous year's same the six months. The steep decline was caused by a severe reduction in orders from customers in the semiconductor fabrication equipment industry. There continues to be no sign of immediate recovery in the semiconductor industry. Management believes a strong sales effort at OMS continues to gain design wins that will provide opportunities for its products in the medical, semiconductor and distribution industries.

Gross profits by subsidiary follows:

		2001	2000	Increase/
				(Decrease)
Micro Motors		\$1,640,000	\$1,111,000	\$529,000
Oregon Micro Systems		736,000	3,855,000	(3,119,000)
	\$_	2,376,000	\$ 4,966,000	\$ (2,590,000)

The Company's consolidated gross profit for the six months ended December 31, 2001 decreased 52% over the same six months in the previous year due to reduced sales at OMS. Gross profit as a percentage of sales decreased to 45% for the six months ended December 31, 2001 compared to 56% for the six months ended December 31, 2000 caused by the lower sales at the higher margined OMS. Gross profit dollars and percentage increased at Micro Motors from 29% to 40% due to sales of higher priced products and manufacturing cost controls.

Operating expenses decreased to \$2,867,000 for the six months ended December 31, 2001 from \$3,575,000 (before unusual charges) for the six months ended December 31, 2000, a decrease of 20%. The decrease is mainly due to the cost cutting at both OMS and Micro Motors and the consolidation of the Micro Motors offices in Santa Ana, California.

Net interest expense decreased \$415,000 in the first six months of fiscal 2001 due to the payoff of the Company's entire bank debt on June 12, 2001 with the use of the proceeds from the sale of the Biotrol and Challenge operations.

The Company's effective tax rate on income (loss) from operations is 40% for the six months ended December 31, 2001, and 2000. The Company's effective tax rate for income from discontinued operations is 40% for the six months ended December 31, 2000.

Net income from continuing operations decreased \$616,000 for the six months ended December 31, 2001 compared to the six months ended December 31, 2000 due to lower sales and gross profits. The Company sustained a net loss from discontinued operations of (\$233,000) net of taxes.

The Company sustained a net income (loss) for the six months ended December 31, 2001 of (\$518,000) ((\$0.06)/share) compared to net income of \$462,000 (\$0.05/share) for the six months ended December 31, 2000.

Real Estate for sale

Management believes it has properly estimated the fair market value for the property held for sale. However, the property is located in an area with few comparable transactions on which to base the estimate. A new real estate agent has been retained to assist in hastening the sale process, which includes continuing reanalysis of the property value. Should real estate prices decline, further provisions for impairment may be necessary.

Income Taxes

Net realizable deferred tax assets of \$948,000 could be reduced in the near term if estimates of the future profitability are reduced or if future changes in the ownership of the Company occur. Management believes it is more likely than not that the net deferred asset is fully realizable and will be offset by future earnings.

Legal Proceedings

The manufacture and distribution of certain products by subsidiaries of the Company involves a risk of legal action, and, from time to time, the Company and its subsidiaries are named as defendants in lawsuits. While the Company's management is confident that these matters will not have a material adverse impact on the financial condition of the Company, there can be no certainty that the Company may not ultimately incur liability or that such liability will not be material and adverse.

Liquidity and Capital Resources

The operations of the Company are conducted primarily through its wholly owned subsidiaries, Micro Motors and OMS. On June 12, 2001 the Company paid off its bank debt of approximately \$5.6 million to Harris Bank and Trust utilizing the proceeds from the sale of substantially all the assets of its Biotrol and Challenge operating subsidiaries. The Company's working capital at December 31, 2001 was approximately \$4.2 million with no bank debt. Of the \$4.2 million of working capital, \$1.9 million is held in the escrow account. Management is working to free up the escrow account as soon as possible, and management believes the EPA settlement should lead to a resolution within the next quarter. The additional issues with the buyer include other government entity legal, compliance and settlement costs. Management is actively seeking a banking relationship to secure a credit facility to provide working capital should the need arise. Management believes that the Company's working capital needs over the next twelve months can be adequately supported by current operations and current cash reserves, although there can be no assurance that such operations and reserves will be sufficient to meet the such working capital requirements. In the event the Company's revenues from operations are materially lower than projected,

cash reserves are insufficient to meet the Company's requirements as a result of such revenue shortfall, and the Company is unsuccessful in its attempts to find alternative sources of capital on terms acceptable to the Company, the resulting lack of liquidity is likely to materially adversely impact the Company's business operations and financial condition.

See discussion of inventory and escrow reserves in the notes to the financial statements.

PART II

OTHER INFORMATION

Item 1 - Legal Proceedings

The Company has received indemnification notices (the "Notices") from Young Colorado, LLC dated November 9, and February 15, 2001, respectively, pursuant to the Agreement for Purchase and Sale of Assets, dated as of June 12, 2001 (the "Agreement") by and among Young Colorado, LLC ("Young"), the Company, Pro-Dex Management, Inc., Biotrol International ("Biotrol") and Challenge Products, Inc. ("Challenge" and together with Biotrol collectively, ("Seller"). Biotrol and Challenge are wholly owned subsidiaries of the Company. In the Notices, Young has notified the Company of various alleged breaches of representations and warranties set forth in the Agreement including (i) Seller's alleged failure to be in compliance with FDA, FDCA, FIFRA, environmental laws and other related laws (ii) Seller's alleged failure to have standard operating procedures and other quality system/current good manufacturing practice procedures, and (iii) certain amounts (stated at \$90,548) alleged owing by Biotrol under a purchase commitment to a third party upon which demand has been received. In addition, the Company has been notified that there are significant compliance costs that must be paid by the Company. Young alleges that the foregoing has resulted in a loss and compliance costs for which Young will be seeking indemnification in accordance with the Agreement, although the amounts of losses and compliance costs have not been determined. Young asserts that such losses and compliance costs could exceed the entire excrow amount of \$2.4 million as established pursuant to the Agreement. As a result, Young has provided the escrow agent a "Buyer's Release Notice" preventing any portion of the escrow amount from being distributed to the Company pending the finalization of the indemnifiable amounts. In February 2002, the Company settled a complaint with the EPA related to one of the claims set forth in the Notices for alleged violations of FIFRA. As a result, the Company will pay \$150,000 to the EPA, payable over a 15 month period. The Company intends to vigorously defend its position with respect to the foregoing allegations and indemnification demands, and protect its rights with respect to the escrow amount

Item 4 – Submission of Matter to a Vote of Security Holders

On November 29, 2001, the company held its 2001 annual Shareholders Meeting. At the Meeting the Company's shareholders (i) elected George J. Isaac and Franklin D. Brown as Class I directors and (ii) ratified the appointment of McGladrey & Pullen, LLP as the Company's independent auditors for the fiscal year ending June 30, 2002. Mr. Isaac received the following votes: For 7,749,965 Against 78,460 Abstain 0. Mr. Brown received the following votes: For 7,749,965 Against 78,460 Abstain 0. The proposal to ratify the appointment of McGladrey & Pullen, LLP received the following votes: For 7,740,900 Against 76,900 Abstain 11,210. The following directors continued service on the Company's Board and were not voted upon by the company's shareholders at the Annual Shareholders Meeting: Robert A. Hovee, Frank H. Zagar, Ronald G. Coss and Kent E Searl.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

February 19, 2002	/s/ Ronald Coss
	Ronald Coss, Chairman
February 19, 2002	/s/ Frank H. Zagar
	Frank H. Zagar, President and CEO

Date: February 19, 2002 /s/ George J. Isaac

George J. Isaac, Chief Financial Officer